Inadequate seroconversion rates in celiac disease after 3 doses of hepatitis B vaccine, administered at 3, 5 and 11 months of life

Agostoni Carlo Virgimio, Boccazzi Antonio, Pontari Sara, Bedogni Giorgio, Prampolini Luigia, Garotta Matteo, Torresani Erminio, Lunghi Giovanna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Celiac disease (CD) is a clinical condition potentially impairing the immune system. We tested the hypothesis that CD could hinder seroconversion following hepatitis B vaccine (HBV). We compared 81 consecutive CD patients (24 male and 57 female) with a median [interquartile range (IQR)] age of 10 (7) yr (range 2-30 yr) and 50 controls (26 male and 24 female) with a median (IQR) age 7 (7) yr (range 1-26 yr) who received a standard immunisation schedule with HBV given at 3, 5 and 11 mo of. The median (IQR) interval from the last dose of HBV was higher in CD patients as compared to controls [10 (7), range 2-29 yr vs. 6 (7), range 1-26 yr; P <0.0001]. The median (IQR) age of gluten introduction was comparable in the two groups [6 (1), range 4-12 mo vs. 6(1), range 5-11 mo]. The median (IQR) duration of gluten intake in the CD group was 3.5 (4.8) yr (range 0.2-12.3 yr). 33 of 81 (40%) CD patients did not seroconvert (anti-HBs <10 IU/mL), compared with 10 of 50 (20%) controls (P <0.05). The odds ratio of a protective anti-HBs titer in CD patients vs. controls was 0.36 (95% 0.16-0.83, P <0.0001), and was not associated with gender, interval from the last administration of HBV, or duration of pre-diagnosis gluten intake in CD patients. Our results are consistent with previous observations that CD patients are less likely to be protected by HBV, which may have important public health implications.

Original languageEnglish
Pages (from-to)173-176
Number of pages4
JournalJournal of Pediatric Infectious Diseases
Volume6
Issue number3
DOIs
Publication statusPublished - 2011

Fingerprint

Hepatitis B Vaccines
Celiac Disease
Glutens
Immunization Schedule
Seroconversion
Immune System
Public Health
Odds Ratio

Keywords

  • Celiac disease
  • HBV vaccine
  • immune network
  • seroconversion

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Cite this

Inadequate seroconversion rates in celiac disease after 3 doses of hepatitis B vaccine, administered at 3, 5 and 11 months of life. / Virgimio, Agostoni Carlo; Antonio, Boccazzi; Sara, Pontari; Giorgio, Bedogni; Luigia, Prampolini; Matteo, Garotta; Erminio, Torresani; Giovanna, Lunghi.

In: Journal of Pediatric Infectious Diseases, Vol. 6, No. 3, 2011, p. 173-176.

Research output: Contribution to journalArticle

Virgimio, Agostoni Carlo ; Antonio, Boccazzi ; Sara, Pontari ; Giorgio, Bedogni ; Luigia, Prampolini ; Matteo, Garotta ; Erminio, Torresani ; Giovanna, Lunghi. / Inadequate seroconversion rates in celiac disease after 3 doses of hepatitis B vaccine, administered at 3, 5 and 11 months of life. In: Journal of Pediatric Infectious Diseases. 2011 ; Vol. 6, No. 3. pp. 173-176.
@article{b5645961a98b4b17921d737a78ca0c9d,
title = "Inadequate seroconversion rates in celiac disease after 3 doses of hepatitis B vaccine, administered at 3, 5 and 11 months of life",
abstract = "Celiac disease (CD) is a clinical condition potentially impairing the immune system. We tested the hypothesis that CD could hinder seroconversion following hepatitis B vaccine (HBV). We compared 81 consecutive CD patients (24 male and 57 female) with a median [interquartile range (IQR)] age of 10 (7) yr (range 2-30 yr) and 50 controls (26 male and 24 female) with a median (IQR) age 7 (7) yr (range 1-26 yr) who received a standard immunisation schedule with HBV given at 3, 5 and 11 mo of. The median (IQR) interval from the last dose of HBV was higher in CD patients as compared to controls [10 (7), range 2-29 yr vs. 6 (7), range 1-26 yr; P <0.0001]. The median (IQR) age of gluten introduction was comparable in the two groups [6 (1), range 4-12 mo vs. 6(1), range 5-11 mo]. The median (IQR) duration of gluten intake in the CD group was 3.5 (4.8) yr (range 0.2-12.3 yr). 33 of 81 (40{\%}) CD patients did not seroconvert (anti-HBs <10 IU/mL), compared with 10 of 50 (20{\%}) controls (P <0.05). The odds ratio of a protective anti-HBs titer in CD patients vs. controls was 0.36 (95{\%} 0.16-0.83, P <0.0001), and was not associated with gender, interval from the last administration of HBV, or duration of pre-diagnosis gluten intake in CD patients. Our results are consistent with previous observations that CD patients are less likely to be protected by HBV, which may have important public health implications.",
keywords = "Celiac disease, HBV vaccine, immune network, seroconversion",
author = "Virgimio, {Agostoni Carlo} and Boccazzi Antonio and Pontari Sara and Bedogni Giorgio and Prampolini Luigia and Garotta Matteo and Torresani Erminio and Lunghi Giovanna",
year = "2011",
doi = "10.3233/JPI-2011-0321",
language = "English",
volume = "6",
pages = "173--176",
journal = "Journal of Pediatric Infectious Diseases",
issn = "1871-0336",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Inadequate seroconversion rates in celiac disease after 3 doses of hepatitis B vaccine, administered at 3, 5 and 11 months of life

AU - Virgimio, Agostoni Carlo

AU - Antonio, Boccazzi

AU - Sara, Pontari

AU - Giorgio, Bedogni

AU - Luigia, Prampolini

AU - Matteo, Garotta

AU - Erminio, Torresani

AU - Giovanna, Lunghi

PY - 2011

Y1 - 2011

N2 - Celiac disease (CD) is a clinical condition potentially impairing the immune system. We tested the hypothesis that CD could hinder seroconversion following hepatitis B vaccine (HBV). We compared 81 consecutive CD patients (24 male and 57 female) with a median [interquartile range (IQR)] age of 10 (7) yr (range 2-30 yr) and 50 controls (26 male and 24 female) with a median (IQR) age 7 (7) yr (range 1-26 yr) who received a standard immunisation schedule with HBV given at 3, 5 and 11 mo of. The median (IQR) interval from the last dose of HBV was higher in CD patients as compared to controls [10 (7), range 2-29 yr vs. 6 (7), range 1-26 yr; P <0.0001]. The median (IQR) age of gluten introduction was comparable in the two groups [6 (1), range 4-12 mo vs. 6(1), range 5-11 mo]. The median (IQR) duration of gluten intake in the CD group was 3.5 (4.8) yr (range 0.2-12.3 yr). 33 of 81 (40%) CD patients did not seroconvert (anti-HBs <10 IU/mL), compared with 10 of 50 (20%) controls (P <0.05). The odds ratio of a protective anti-HBs titer in CD patients vs. controls was 0.36 (95% 0.16-0.83, P <0.0001), and was not associated with gender, interval from the last administration of HBV, or duration of pre-diagnosis gluten intake in CD patients. Our results are consistent with previous observations that CD patients are less likely to be protected by HBV, which may have important public health implications.

AB - Celiac disease (CD) is a clinical condition potentially impairing the immune system. We tested the hypothesis that CD could hinder seroconversion following hepatitis B vaccine (HBV). We compared 81 consecutive CD patients (24 male and 57 female) with a median [interquartile range (IQR)] age of 10 (7) yr (range 2-30 yr) and 50 controls (26 male and 24 female) with a median (IQR) age 7 (7) yr (range 1-26 yr) who received a standard immunisation schedule with HBV given at 3, 5 and 11 mo of. The median (IQR) interval from the last dose of HBV was higher in CD patients as compared to controls [10 (7), range 2-29 yr vs. 6 (7), range 1-26 yr; P <0.0001]. The median (IQR) age of gluten introduction was comparable in the two groups [6 (1), range 4-12 mo vs. 6(1), range 5-11 mo]. The median (IQR) duration of gluten intake in the CD group was 3.5 (4.8) yr (range 0.2-12.3 yr). 33 of 81 (40%) CD patients did not seroconvert (anti-HBs <10 IU/mL), compared with 10 of 50 (20%) controls (P <0.05). The odds ratio of a protective anti-HBs titer in CD patients vs. controls was 0.36 (95% 0.16-0.83, P <0.0001), and was not associated with gender, interval from the last administration of HBV, or duration of pre-diagnosis gluten intake in CD patients. Our results are consistent with previous observations that CD patients are less likely to be protected by HBV, which may have important public health implications.

KW - Celiac disease

KW - HBV vaccine

KW - immune network

KW - seroconversion

UR - http://www.scopus.com/inward/record.url?scp=84857007768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857007768&partnerID=8YFLogxK

U2 - 10.3233/JPI-2011-0321

DO - 10.3233/JPI-2011-0321

M3 - Article

VL - 6

SP - 173

EP - 176

JO - Journal of Pediatric Infectious Diseases

JF - Journal of Pediatric Infectious Diseases

SN - 1871-0336

IS - 3

ER -